×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD
clinical
967 words
KG: ent-clin-07e2c8f9
2026-03-26
kind:clinical-trial
section:clinical-trials
state:published
Contents
PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD
Knowledge Graph
Related Hypotheses (14)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Cryptic Exon Silencing Restoration
Score: 0.46
Cross-Seeding Prevention Strategy
Score: 0.45
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
Phase-Separated Organelle Targeting
Score: 0.52
Noradrenergic-Tau Propagation Blockade
Score: 0.51
Stress Granule Phase Separation Modulators
Score: 0.49
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.44
Synaptic Vesicle Tau Capture Inhibition
Score: 0.34
Show 9 more
Related Analyses (6)
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Show 1 more
Related Experiments (5)
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
See Also (15)
Yoga Therapy for Neurodegeneration
therapeutic · Pages share 6 hypotheses
YAP/TEAD Pathway Modulators for Neurodegeneration
therapeutic · Pages share 6 hypotheses
Wnt Signaling Modulators for Neurodegeneration
therapeutic · Pages share 6 hypotheses
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 6 hypotheses
Vitamin B Complex Therapy for Neurodegeneration
therapeutic · Pages share 6 hypotheses
VIP/VPAC Receptor Modulators for Neurodegeneration
therapeutic · Pages share 6 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 6 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 6 hypotheses
tudca-udca-neurodegeneration
therapeutic · Pages share 6 hypotheses
TRPM8 Agonists for Neurodegeneration
therapeutic · Pages share 6 hypotheses
Triple Incretin Agonists (GLP-1/GIP/Glucagon) for Neuro
therapeutic · Pages share 6 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 6 hypotheses
Transcranial Magnetic Stimulation Therapy for Neurodege
therapeutic · Pages share 6 hypotheses
TLR7/8/9 Antagonists for Neurodegeneration
therapeutic · Pages share 6 hypotheses
TLR4 Antagonists for Neurodegeneration
therapeutic · Pages share 6 hypotheses
Show 10 more